The ACTG is excited to share the publication in the New England Journal of Medicine of “Four-month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.” This paradigm-shifting study demonstrates the feasibility of decreasing the length of TB treatment by one-third – a profound advancement in the management of a disease that continues to proliferate globally. Study 31/A5349, which was also presented at the Union World Conference on Lung Health in October 2020, showed that the four-month regimen of rifapentine, isoniazid, pyrazinamide, and moxifloxacin (RPT-MOX) was non-inferior to the currently recommended six-month regimen of rifampicin, isoniazid, ethambutol, and pyrazinamide for the treatment of drug-susceptible pulmonary TB. RPT-MOX was also safe and well-tolerated by study participants. A second four-month regimen of rifapentine, isoniazid, pyrazinamide, and ethambutol did not meet the non-inferiority margin.
To read more click here.